Pfizer Inc. $PFE Shares Acquired by SG Americas Securities LLC

Key Points

• SG Americas Securities LLC boosted its Pfizer stake by 206.1% in Q4, buying 3,644,809 shares to hold 5,412,966 shares (about 0.10% of the company) valued at roughly $134.8 million.
• Pfizer beat Q4 estimates with EPS of $0.66 (vs. $0.57 est.) and revenue of $17.56B (vs. $16.93B), carries a market cap near $152.2B, and has an average analyst rating of "Hold" with a $28.14 consensus price target.
• Pfizer’s Phase‑3 Lyme vaccine showed ~73% efficacy in pre‑specified analyses but missed its formal primary endpoint due to a low number of infection events, and the company plans to seek regulatory submissions despite heightened approval and timing uncertainty.

SG Americas Securities LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 206.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,412,966 shares of the biopharmaceutical company's stock after purchasing an additional 3,644,809 shares during the quarter. SG Americas Securities LLC owned 0.10% of Pfizer worth $134,783,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PFE. Fiduciary Alliance LLC boosted its stake in shares of Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company's stock valued at $3,701,000 after buying an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Pfizer during the third quarter worth approximately $3,019,000. Money Concepts Capital Corp raised its holdings in Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock valued at $6,325,000 after acquiring an additional 57,188 shares in the last quarter. Vista Investment Partners LLC raised its holdings in Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company's stock valued at $1,774,000 after acquiring an additional 48,900 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA purchased a new position in Pfizer in the third quarter worth approximately $16,613,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.7%

Shares of NYSE:PFE opened at $26.77 on Tuesday. The firm has a 50 day simple moving average of $26.71 and a 200-day simple moving average of $25.63. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $152.23 billion, a PE ratio of 19.68 and a beta of 0.47.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the firm posted $0.63 EPS. The company's revenue was down 1.2% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on PFE. Zacks Research raised shares of Pfizer from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 24th. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the stock an "underperform" rating in a research report on Wednesday, December 17th. Barclays began coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an "underweight" rating and a $25.00 target price for the company. HSBC increased their target price on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, March 17th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and set a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.14.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 topline shows robust efficacy (~73% in pre-specified analyses), signaling clear commercial potential if regulators accept the data and approve the shot. BusinessWire: Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
• Positive Sentiment: Pfizer’s defensive income profile (high dividend yield cited in market coverage) and recent YTD recovery are attracting dividend‑focused investors, providing demand support amid market volatility. MarketBeat: 5 High-Yield Stocks to Shield Your Portfolio From the Storm
• Positive Sentiment: Technical/market narrative: coverage notes Pfizer is showing signs of outperformance versus prior years, which can attract momentum and rotation flows into the name. Fool: Pfizer Stock Is Doing Something It Hasn't Done Since 2022
• Neutral Sentiment: Pfizer says it will pursue regulatory submissions despite the trial missing its formal primary endpoint — this keeps an approval path alive but raises review uncertainty and timing questions. CNBC: Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
• Negative Sentiment: The trial failed to meet its primary endpoint due to a low number of infection events, making the results statistically inconclusive and injecting regulatory and commercial risk; partner Valneva’s stock plunged on the news, reflecting investor concern about approval odds and program economics. WSJ: Pfizer’s Lyme Vaccine Shows Strong Efficacy but Misses Mark in Study

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.